Our study revealed significantly elevated concentrations of all tested biomarkers reflecting neurodegeneration in the MS group, among which NfL seemed to have the highest diagnostic value as a biomarker at disease onset. The gene discussed is NEFL; the disease is myeloid sarcoma.